Semaglutide differs from other GLP*1 receptor agonists by having a longer half-life and producing greater weight loss
Atherosclerotic Plaque Pathways Targeted by GLP-1RAs The use of liraglutide and semaglutide, as shown in the LEADER and SUSTAIN-6 trials, reduces the occurrence of MACEs in high-risk CVD patients with diabetes
Common adverse effects of GLP-1 receptor agonistsincluding nausea, vomiting, diarrhea, and constipationoccur with similar frequency in patients with and without thyroid disease
Inspect the solution if it appears cloudy, discoloured, or contains visible particles, do not use it
This warning was not included in the initial drug-warning labels of many semaglutide drugs
Are GLP-1 agonists safe for everyone